The History of Intermittent Androgen Deprivation Therapy - A Canadian Story

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2020 Jun 12

PMID 32525797

Citations 3

Authors

Laurence Klotz

Affiliations

Soon will be listed here.

Citing Articles

Factors Associated with Potentially Inappropriate Prescribing in Patients with Prostate Cancer.

Peulic M, Zivkovic Zaric R, Stojadinovic M, Peulic M, Gavrilovic J, Zivkovic Radojevic M J Clin Med. 2025; 14(3).

PMID: 39941490 PMC: 11818911. DOI: 10.3390/jcm14030819.

Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence.

Derbal Y Clin Med Insights Oncol. 2025; 19():11795549241311408.

PMID: 39776668 PMC: 11701910. DOI: 10.1177/11795549241311408.

Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise?.

Nilsen T, Johansen S, Thorsen L, Fairman C, Wisloff T, Raastad T Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409505 PMC: 8997930. DOI: 10.3390/ijerph19073820.

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.

Choi E, Buie J, Camacho J, Sharma P, de Riese W Res Rep Urol. 2022; 14:87-108.

PMID: 35386270 PMC: 8977476. DOI: 10.2147/RRU.S303215.

Everything old is new again.

Casey R Can Urol Assoc J. 2020; 14(11):E615.

PMID: 33213698 PMC: 7673823. DOI: 10.5489/cuaj.6995.

References

Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg S . Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer. 2008; 6(1):46-52. DOI: 10.3816/CGC.2008.n.008. View

Klotz L . Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. Curr Urol Rep. 2013; 14(3):159-67. DOI: 10.1007/s11934-013-0325-x. View

Huggins C, Hodges C . Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 168(1):9-12. DOI: 10.1016/s0022-5347(05)64820-3. View

Bruchovsky N, Klotz L, Crook J, Goldenberg S . Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer. 2007; 109(5):858-67. DOI: 10.1002/cncr.22464. View

Klotz L, Nabid A, Higano C, Ryanm C, Kebabdjian M, Chin J . Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. Can Urol Assoc J. 2014; 8(11-12):E789-94. PMC: 4250242. DOI: 10.5489/cuaj.2332. View

Klotz L, Loblaw A, Siemens R, Ouellette P, Kapoor A, Kebabdjian M . A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical.... J Urol. 2018; 200(2):335-343. DOI: 10.1016/j.juro.2018.03.010. View

Bruchovsky N, Rennie P, Coldman A, Goldenberg S, To M, Lawson D . Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990; 50(8):2275-82. View

Chang S, Liao J, Shinghal R . Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis. J Urol. 2009; 182(1):255-60. DOI: 10.1016/j.juro.2009.02.141. View

Sato N, Gleave M, Bruchovsky N, Rennie P, Goldenberg S, Lange P . Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996; 58(2):139-46. DOI: 10.1016/0960-0760(96)00018-0. View

10.

Klotz L, Shayegan B, Guillemette C, Collins L, Gotto G, Guerette D . Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement. Can Urol Assoc J. 2018; 12(2):30-37. PMC: 5937399. DOI: 10.5489/cuaj.5116. View

11.

Hussain M, Tangen C, Berry D, Higano C, Crawford E, Liu G . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013; 368(14):1314-25. PMC: 3682658. DOI: 10.1056/NEJMoa1212299. View

12.

Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Velot L . Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. J Urol. 2019; 203(5):940-948. DOI: 10.1097/JU.0000000000000699. View

13.

Piaggio G, Elbourne D, Pocock S, Evans S, Altman D . Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012; 308(24):2594-604. DOI: 10.1001/jama.2012.87802. View

14.

Bruchovsky N, Klotz L, Sadar M, Crook J, Hoffart D, GODWIN L . Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol. 2000; 4(3):191-9;discussion 201. View

15.

Klotz L, Herr H, Morse M, WHITMORE Jr W . Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986; 58(11):2546-50. DOI: 10.1002/1097-0142(19861201)58:11<2546::aid-cncr2820581131>3.0.co;2-n. View

16.

Crook J, OCallaghan C, Duncan G, Dearnaley D, Higano C, Horwitz E . Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012; 367(10):895-903. PMC: 3521033. DOI: 10.1056/NEJMoa1201546. View

17.

Klotz L, OCallaghan C, Ding K, Toren P, Dearnaley D, Higano C . Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015; 33(10):1151-6. PMC: 4372851. DOI: 10.1200/JCO.2014.58.2973. View

18.

Toren P, Hoffman A, Ding K, Joncas F, Turcotte V, Caron P . Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Analysis of the PR.7 Trial. Clin Cancer Res. 2018; 24(21):5305-5312. DOI: 10.1158/1078-0432.CCR-18-1187. View

19.

Akakura K, Bruchovsky N, Goldenberg S, Rennie P, Buckley A, Sullivan L . Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993; 71(9):2782-90. DOI: 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z. View

20.

Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris W . Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer. 2006; 107(2):389-95. DOI: 10.1002/cncr.21989. View